Alliancebernstein L.P. Tricida, Inc. Transaction History

Alliancebernstein L.P.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$0.14 - $12.49 $27,622 - $2.46 Million	197,300 Added 1108.43%	215,100 $32,000
Q3 2022 Nov 15, 2022	BUY	$8.51 - $13.6 $66,378 - $106,080	7,800 Added 78.0%	17,800 $187,000
Q2 2022 Aug 15, 2022	BUY	$7.31 - $11.85 $73,100 - $118,500	10,000 New	10,000 $97,000
Q2 2021 Jul 30, 2021	SELL	$3.95 - $5.41 $130,745 - $179,071	-33,100 Closed	0 $0
Q1 2021 May 06, 2021	SELL	$4.52 - $7.8 $21,243 - $36,660	-4,700 Reduced 12.43%	33,100 $175,000
Q4 2020 Feb 08, 2021	SELL	$4.37 - $9.46 $10,051 - $21,758	-2,300 Reduced 5.74%	37,800 $266,000
Q3 2020 Nov 12, 2020	SELL	$8.56 - $26.93 $9,416 - $29,623	-1,100 Reduced 2.67%	40,100 $363,000
Q2 2020 Aug 13, 2020	BUY	$21.21 - $31.55 $197,253 - $293,415	9,300 Added 29.15%	41,200 $1.13 Million
Q1 2020 May 14, 2020	SELL	$18.43 - $38.04 $22,116 - $45,648	-1,200 Reduced 3.63%	31,900 $702,000
Q2 2019 Aug 14, 2019	BUY	$31.16 - $39.46 $473,632 - $599,792	15,200 Added 84.92%	33,100 $1.31 Million
Q1 2019 May 14, 2019	BUY	$19.96 - $38.62 $141,716 - $274,202	7,100 Added 65.74%	17,900 $691,000
Q4 2018 Feb 13, 2019	BUY	$23.57 - $32.33 $254,556 - $349,164	10,800 New	10,800 $255,000

30K

124K

46.5K

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

Stay updated on Alliancebernstein L.P. with notifications on news.